Additionally, there were notable variations in the prevalence of diabetes, CKD, PA, and dyslipidemia, as well as differences in smoking status and the proportion of participants taking statins, aspirin, angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin receptor blockers (ARBs), spironolactone, and glucose-lowering agents. The gene discussed is ACE; the disease is metabolic syndrome.